Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTAIN: Ranibizumab and Antibody Profiles in nAMD
NCT02843490Phase 4Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Johannes Gutenberg University Mainz. Primary endpoint: Best Corrected Visual Acuity at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02843490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843490.